Axcelis Technologies, Inc.

Axcelis Technologies, Inc. (ACLS) Stock Analysis

$108.350

-6.360 (-5.87%)At close

Loading chart…
High
114.265
Open
112.780
VWAP
110.27
Volume
283.26K
Mkt Cap
4.54B
Low
108.185
Amount
31.23M
EV/EBITDA, TTM
29.15

Axcelis Technologies, Inc. is primarily a producer of ion implantation equipment used in the fabrication of semiconductor chips in the United States, Europe, and Asia. The Company is focused on developing enabling process applications through the design, manufacture and complete life cycle support of ion implantation systems, one of the enabling steps in the IC manufacturing process. The Company's products include High Current, Medium Energy, High Energy, Mid Current, and GSD Ovation. The Company's Purion H6 next generation high current ion implanters deliver process control by leveraging its spot beam architecture, optimized for the full spectrum of high-current applications. The Company's Purion H200 is its state-of-the-art single wafer high current medium energy implanter. Its Purion XE Series high energy ion implanters use RF Linear Accelerator (LINAC) technology. The Company's Purion M ion implanters offer the broadest spectrum of mid-current doses available.

AI analysis of Axcelis Technologies, Inc. (ACLS)

Sell

Axcelis Technologies Inc is not a good buy right now due to a significant decline in its stock price and negative technical indicators. The current price of $108.35 represents a 19.57% drop over the last five days, and the RSI is at a very low 17.212, indicating oversold conditions. Additionally, insider selling has surged by 2536.94%, which raises concerns about the confidence of those closest to the company. While analysts have a price target as high as $198, the recent downgrade by Craig-Hallum to a Hold rating with a target of $140 suggests caution. The main risk is the potential for further price declines given the current market sentiment and technical indicators.

Valuation Metrics

The current forward P/E ratio for Axcelis Technologies, Inc. (ACLS) is 19.84, compared to its 5-year average forward P/E of 19.78.

Forward P/E

Fair
5Y Average P/E
19.78
Current P/E
19.84
Overvalued
26.80
Undervalued
12.76

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
18.10
Current EV/EBITDA
29.15
Overvalued
34.42
Undervalued
1.78

Forward P/S

Fair
5Y Average P/S
3.29
Current P/S
3.38
Overvalued
4.23
Undervalued
2.36

Alphio AI Price Scenarios for ACLS

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ACLS

$45.27

Scenario price

B

Base

Base · 50%ACLS

$41.15

Scenario price

B

Bear

Bear · 25%ACLS

$27.78

Scenario price

Whales holding ACLS

W

Weiss Asset Management, LLC

+ HoldingACLS

-4.94%

3M Return

Events Timeline

2026-09-08 (ET)

08:30:00

Axcelis to Invest $35M in New Manufacturing Facility

2026-08-06 (ET)

07:30:00

Sees Q3 Revenue at $230M, Consensus $214.77M

07:30:00

Q2 Revenue Reaches $215.2M, Exceeds Expectations

2026-07-02 (ET)

12:30:00

Axcelis Stock Drops 15.1% to $151.35

2026-06-09 (ET)

10:10:00

Axcelis Stock Rises 17.6%

News

ACLS FAQ — answered by Alphio AI

Axcelis Technologies, Inc. is primarily a producer of ion implantation equipment used in the fabrication of semiconductor chips in the United States, Europe, and Asia. The Company is focused on developing enabling process applications through the design, manufacture and complete life cycle support of ion implantation systems, one of the enabling steps in the IC manufacturing process. The Company's products include High Current, Medium Energy, High Energy, Mid Current, and GSD Ovation. The Company's Purion H6 next generation high current ion implanters deliver process control by leveraging its spot beam architecture, optimized for the full spectrum of high-current applications. The Company's Purion H200 is its state-of-the-art single wafer high current medium energy implanter. Its Purion XE Series high energy ion implanters use RF Linear Accelerator (LINAC) technology. The Company's Purion M ion implanters offer the broadest spectrum of mid-current doses available. It operates in the Technology sector (SPECIAL INDUSTRY MACHINERY, NEC industry).

Axcelis Technologies Inc is not a good buy right now due to a significant decline in its stock price and negative technical indicators. The current price of $108.35 represents a 19.57% drop over the last five days, and the RSI is at a very low 17.212, indicating oversold conditions. Additionally, insider selling has surged by 2536.94%, which raises concerns about the confidence of those closest to the company. While analysts have a price target as high as $198, the recent downgrade by Craig-Hallum to a Hold rating with a target of $140 suggests caution. The main risk is the potential for further price declines given the current market sentiment and technical indicators.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading